Drug Shortage Report for DALACIN C PHOSPHATE
Report ID | 153655 |
Drug Identification Number | 00260436 |
Brand name | DALACIN C PHOSPHATE |
Common or Proper name | DALACIN C PHOSPHATE |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | CLINDAMYCIN |
Strength(s) | 150MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 60mL vial |
ATC code | J01FF |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-03-23 |
Estimated end date | |
Actual end date | 2022-05-04 |
Shortage status | Resolved |
Updated date | 2022-05-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2022-05-05 | French | Compare |
v8 | 2022-05-05 | English | Compare |
v7 | 2022-03-24 | English | Compare |
v6 | 2022-03-23 | French | Compare |
v5 | 2022-03-23 | English | Compare |
v4 | 2022-03-11 | French | Compare |
v3 | 2022-03-11 | English | Compare |
v2 | 2022-01-27 | French | Compare |
v1 | 2022-01-27 | English | Compare |
Showing 1 to 9 of 9